Literature DB >> 25499535

The transitional association between β-amyloid pathology and regional brain atrophy.

Philip S Insel1, Niklas Mattsson2, Michael C Donohue3, R Scott Mackin4, Paul S Aisen5, Clifford R Jack6, Leslie M Shaw7, John Q Trojanowski7, Michael W Weiner8.   

Abstract

INTRODUCTION: Alzheimer's disease (AD) is characterized by the accumulation of β-amyloid (Aβ) associated with brain atrophy and cognitive decline. The functional form to model the association between Aβ and regional brain atrophy has not been well defined. To determine the relationship between Aβ and atrophy, we compared the performance of the usual dichotomization of cerebrospinal fluid (CSF) Aβ to identify subjects as Aβ+ and Aβ- with a trilinear spline model of CSF Aβ.
METHODS: One hundred and eighty-three subjects with mild cognitive impairment and 108 cognitively normal controls with baseline CSF Aβ and up to 4 years of longitudinal magnetic resonance imaging data from the Alzheimer's Disease Neuroimaging Initiative were analyzed using mixed-effects regression. Piecewise-linear splines were used to evaluate the nonlinear nature of the association between CSF Aβ and regional atrophy and to identify points of acceleration of atrophy with respect to Aβ. Several parameterizations of CSF Aβ were compared using likelihood ratio tests and the Akaike information criterion. Periods of acceleration of atrophy in which subjects transition from CSF Aβ negativity to CSF Aβ positivity were estimated from the spline models and tested for significance.
RESULTS: Spline models resulted in better fits for many temporal and parietal regions compared with the dichotomous models. The trilinear model showed that periods of acceleration of atrophy varied greatly by region with early changes seen in the insula, amygdala, precuneus, hippocampus, and other temporal regions, occurring before the clinical threshold for CSF Aβ positivity. DISCUSSION: The use of piecewise-linear splines provides an improved model of the nonlinear association between CSF Aβ and regional atrophy in regions implicated in the progression of AD. The important biological finding of this work is that some brain regions show periods of accelerated volume loss well before the CSF Aβ42 threshold. This implies that signs of brain atrophy develop before the current conventional definition of "preclinical AD".
Copyright © 2015 The Alzheimer's Association. All rights reserved.

Entities:  

Keywords:  ADNI; Alzheimer's disease; Atrophy; Beta amyloid; Trilinear

Mesh:

Substances:

Year:  2014        PMID: 25499535      PMCID: PMC4461550          DOI: 10.1016/j.jalz.2014.11.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  31 in total

1.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

2.  Automatically parcellating the human cerebral cortex.

Authors:  Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Cereb Cortex       Date:  2004-01       Impact factor: 5.357

3.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors:  Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

4.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 6.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Authors:  Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2008-04       Impact factor: 4.813

8.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

9.  The methodology of studying decline in Alzheimer's disease.

Authors:  J O Brooks; H C Kraemer; E D Tanke; J A Yesavage
Journal:  J Am Geriatr Soc       Date:  1993-06       Impact factor: 5.562

10.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Authors:  Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  21 in total

1.  When does cognitive decline begin? A systematic review of change point studies on accelerated decline in cognitive and neurological outcomes preceding mild cognitive impairment, dementia, and death.

Authors:  Justin E Karr; Raquel B Graham; Scott M Hofer; Graciela Muniz-Terrera
Journal:  Psychol Aging       Date:  2018-03

2.  Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Authors:  Philip S Insel; Niklas Mattsson; R Scott Mackin; Michael Schöll; Rachel L Nosheny; Duygu Tosun; Michael C Donohue; Paul S Aisen; William J Jagust; Michael W Weiner
Journal:  Neurology       Date:  2016-04-15       Impact factor: 9.910

Review 3.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

4.  Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline.

Authors:  I K Martikainen; N Kemppainen; J Johansson; J Teuho; S Helin; Y Liu; S Helisalmi; H Soininen; R Parkkola; T Ngandu; M Kivipelto; J O Rinne
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-13       Impact factor: 3.825

5.  Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

Authors:  Clifford R Jack; Josephine Barnes; Matt A Bernstein; Bret J Borowski; James Brewer; Shona Clegg; Anders M Dale; Owen Carmichael; Christopher Ching; Charles DeCarli; Rahul S Desikan; Christine Fennema-Notestine; Anders M Fjell; Evan Fletcher; Nick C Fox; Jeff Gunter; Boris A Gutman; Dominic Holland; Xue Hua; Philip Insel; Kejal Kantarci; Ron J Killiany; Gunnar Krueger; Kelvin K Leung; Scott Mackin; Pauline Maillard; Ian B Malone; Niklas Mattsson; Linda McEvoy; Marc Modat; Susanne Mueller; Rachel Nosheny; Sebastien Ourselin; Norbert Schuff; Matthew L Senjem; Alix Simonson; Paul M Thompson; Dan Rettmann; Prashanthi Vemuri; Kristine Walhovd; Yansong Zhao; Samantha Zuk; Michael Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

6.  Associations Between Sub-Threshold Amyloid-β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE ɛ4 Carrier Status in Cognitively Normal Older Adults.

Authors:  Dong Woo Kang; Sheng-Min Wang; Yoo Hyun Um; Nak Young Kim; Chang Uk Lee; Hyun Kook Lim
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

7.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

8.  Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals.

Authors:  Ivan Koychev; Nemanja Vaci; Murat Bilgel; Yang An; Graciela Terrera Muniz; Dean F Wong; John Gallacher; Abhay Mogekhar; Marilyn Albert; Susan M Resnick
Journal:  Alzheimers Dement (Amst)       Date:  2020-03-22

Review 9.  2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  A Leuzy; N J Ashton; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-05       Impact factor: 9.236

10.  Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?

Authors:  Ioannis Tarnanas; Anthoula Tsolaki; Mark Wiederhold; Brenda Wiederhold; Magda Tsolaki
Journal:  Alzheimers Dement (Amst)       Date:  2015-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.